News & Updates

Use of the lung immune prognostic index (LIPI) score can help predict the efficacy of combination therapy of programmed cell death (PD)-1/PD-ligand 1 (PD-L1) blockade and chemotherapy (CT) in patients with advanced nonsmall cell lung cancer (NSCLC), suggests a study.

Patients with nonsmall cell lung cancer (NSCLC) who have been treated with neoadjuvant immunotherapy show greater response than those treated with neoadjuvant chemotherapy (CT), as shown in a study. Treatment-related adverse events (TRAEs) are similar between the two groups.

Several forms of serum vitamin A and E were associated with prostate cancer risk, with significant effect modification by smoking and alcohol consumption status, according to an analysis that used data from the Singapore Prostate Cancer Study.

In the phase III MARIPOSA trial, the amivantamab-lazertinib cocktail outdid osimertinib as first-line (1L) treatment for EGFR-mutated, advanced non-small cell lung cancer (NSCLC).

Prolonged exposure to air pollution appears to put women at increased risk of breast cancer, according to data from the French E3N cohort.

Diabetes and higher body mass index (BMI) contribute to pathological upstaging in renal cell carcinoma, according to a study. Preoperative tumour size, increased age, and male sex are also significantly associated with upstaging.

In patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, adding pembrolizumab to concurrent chemoradiotherapy (cCRT) significantly improves progression-free survival (PFS) vs cCRT alone, according to results of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study presented at European Society for Medical Oncology Congress 2023 (ESMO 2023).